日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors

MEK抑制剂selumetinib联合pembrolizumab治疗晚期或转移性实体瘤的1期临床试验

Chénard-Poirier, Maxime; Hansen, Aaron R; Gutierrez, Martin E; Rasco, Drew; Xing, Yan; Chen, Lin-Chi; Zhou, Heng; Webber, Andrea L; Freshwater, Tomoko; Sharma, Manish R

Early-to-mid stage idiopathic Parkinson's disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females

早期至中期特发性帕金森病患者体内CD8 T细胞的细胞毒性和分化能力在女性中表现出增强。

Christophe M Capelle ,Séverine Ciré ,Fanny Hedin ,Maxime Hansen ,Lukas Pavelka ,Kamil Grzyb ,Dimitrios Kyriakis ,Oliver Hunewald ,Maria Konstantinou ,Dominique Revets ,Vera Tslaf ,Tainá M Marques ,Clarissa P C Gomes ,Alexandre Baron ,Olivia Domingues ,Mario Gomez ,Ni Zeng ,Fay Betsou ,Patrick May ,Alexander Skupin ,Antonio Cosma ,Rudi Balling ,Rejko Krüger ,Markus Ollert ,Feng Q Hefeng